Amicus Therapeutics (FOLD) 7.94 $FOLD Look for Shares of

New Post Public Reply Private Reply Replies (0) Message Board

Sep 21, 2016 at 7:01 PM

Amicus Therapeutics (FOLD) 7.94 $FOLD

Look for Shares of Amicus Therapeutics to Potentially Pullback after Yesterday's 7.20% Rise
Comtex SmarTrend(R) - Tue Sep 20, 3:33PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $7.61 to a high of $8.35. Yesterday, the shares gained 7.2%, which took the trading range above the 3-day high of $7.94 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FOLD: 7.94 (+0.05)

UPDATE -- Amicus Therapeutics to Present at Bank of America Merrill Lynch Global Healthcare Conference 2016
GlobeNewswire - Tue Sep 13, 10:51AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch Global Healthcare Conference 2016 on September 14, 2016 in London, UK at 9:45am UTC (5:45am ET).
FOLD: 7.94 (+0.05)

Amicus Therapeutics to Present at Bank of America Merrill Lynch Global Healthcare Conference 2016
GlobeNewswire - Mon Sep 12, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch Global Healthcare Conference 2016 on September 14, 2016 in London, UK at 1:45pm UTC (8:45am ET).
FOLD: 7.94 (+0.05)

Amicus Therapeutics to Present at Robert W. Baird & Co. 2016 Healthcare Conference
GlobeNewswire - Thu Sep 01, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will participate in a corporate overview and fireside chat at the Robert W. Baird & Co. 2016 Healthcare Conference in New York, NY on Wednesday, September 7 at 3:10pm ET.
FOLD: 7.94 (+0.05)

Amicus Therapeutics to Highlight Fabry Disease Program at Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
GlobeNewswire - Wed Aug 31, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that 7 posters highlighting its Fabry program will be included in the Society for the Study of Inborn Errors of Metabolism's 2016 SSIEM Annual Symposium to be held September 6-9, 2016 in Rome, Italy.
FOLD: 7.94 (+0.05)

UPDATE -- New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
GlobeNewswire - Wed Aug 10, 5:05PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 (FACETS) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat in individuals with Fabry disease were published in the August 11 issue of the New England Journal of Medicine (NEJM). A copy of the manuscript can be found here and in the Science & Technology section of the Amicus Therapeutics corporate website at www.amicusrx.com.
FOLD: 7.94 (+0.05)

New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
GlobeNewswire - Wed Aug 10, 4:18PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 (FACETS) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat in individuals with Fabry disease were published in the June 9 issue of the New England Journal of Medicine (NEJM). A copy of the manuscript can be found here and in the Science & Technology section of the Amicus Therapeutics corporate website at www.amicusrx.com.
FOLD: 7.94 (+0.05)

Amicus Therapeutics Announces Second Quarter 2016 Financial Results and Corporate Updates
GlobeNewswire - Tue Aug 09, 6:31AM CDT
Significant Progress with EU Galafold Launch and Regulatory Submissions
FOLD: 7.94 (+0.05)

Amicus Therapeutics to Submit Japanese New Drug Application for Migalastat for Fabry Disease in 1H17
GlobeNewswire - Wed Aug 03, 6:30AM CDT
Pre-Submission Meeting Completed with Pharmaceuticals and Medical Devices Agency (PMDA) in Japan
FOLD: 7.94 (+0.05)

Amicus Therapeutics to Announce Second Quarter 2016 Financial Results on August 9, 2016
GlobeNewswire - Mon Aug 01, 3:02PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, August 9, 2016 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2016.
FOLD: 7.94 (+0.05)

Dr. Ron Nardi Joins viDA Therapeutics Science Advisory Board
CNW Group - Wed Jun 15, 9:59AM CDT
viDA Therapeutics, Inc. (viDA) announced today that Dr. Ron Nardi has been appointed to the Science Advisory Board (SAB).
FOLD: 7.94 (+0.05)

Amicus Therapeutics Appoints Craig A. Wheeler to Board of Directors
GlobeNewswire - Fri Jun 10, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced the election and appointment of Craig A. Wheeler to its Board of Directors, effective immediately. In addition, Amicus announced that John F. Crowley, Margaret G. McGlynn, Michael G. Raab, and Glenn P. Sblendorio were re-elected at the 2016 Annual Meeting of Stockholders.
FOLD: 7.94 (+0.05)

Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq

GNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the election of Bradley Campbell to the Company's Board of Directors. Mr. Campbell brings to Progenics extensive experience in the biopharmaceutical industry, with particular expertise in the areas of corporate strategy, commercial operations and planning, business development and sales and marketing. He currently serves as President and Chief Operating Officer of Amicus Therapeutics, a biotechnology company focused on the development of therapies for a broad range of rare and orphan diseases.
PGNX: 6.24 (+0.06), FOLD: 7.94 (+0.05)

Amicus Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Wed Jun 01, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the Goldman Sachs 37 Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 7, 2016 at 2:40 p.m. PT.
FOLD: 7.94 (+0.05)

Amicus Therapeutics Announces European Commission Approval for Galafold(TM) (Migalastat) in Patients with Fabry Disease in European Union
GlobeNewswire - Tue May 31, 6:30AM CDT
Launch has Begun in Germany
FOLD: 7.94 (+0.05)

Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Thu May 05, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Wednesday, May 11, 2016 at 4:20 p.m. PT.
FOLD: 7.94 (+0.05)

Amicus Therapeutics reports 1Q loss
Automated Insights - Tue May 03, 7:01AM CDT
CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Tuesday reported a loss of $43.7 million in its first quarter.
FOLD: 7.94 (+0.05)

Amicus Therapeutics Announces First Quarter 2016 Financial Results and Corporate Updates
GlobeNewswire - Tue May 03, 6:00AM CDT
Positive CHMP Opinion for Broad Label of Migalastat for Fabry Disease in Patients with Amenable Mutations
FOLD: 7.94 (+0.05)

Merck (MRK) Q1 Earnings: Can the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:12AM CDT
Will Merck (MRK) maintain its impressive track record and deliver a positive earnings surprise this quarter as well?
MRK: 62.70 (+0.76), BIND: 0.78 (-0.09), CHMA: 2.60 (-0.05), FOLD: 7.94 (+0.05)

Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 116.96 (-0.18), SPPI: 4.47 (-0.15), BIND: 0.78 (-0.09), FOLD: 7.94 (+0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Historic Records Set at 2026 CNO Monumental Marathon

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Johnson & Johnson Unveils Promising PsA Treatment Data

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

NatGold Pulling NATG From MEXC Amid Security Concerns

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Invasive Procedures Don't Extend Life in Stable Heart Disease

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Evaluating GLP-1 Telehealth? Key Questions to Consider

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

2027 Toy of the Year Finalists Energize Play Market

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Boston STEM Expo Sparks Young Minds in Engineering

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...